Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.

IF 1 4区医学 Q4 CLINICAL NEUROLOGY Noropsikiyatri Arsivi-Archives of Neuropsychiatry Pub Date : 2024-11-30 eCollection Date: 2024-01-01 DOI:10.29399/npa.28712

Hua Yang, Haili Wu

{"title":"Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.","authors":"Hua Yang, Haili Wu","doi":"10.29399/npa.28712","DOIUrl":null,"url":null,"abstract":"Introduction: First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.Methods: A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.Results: A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.Conclusion: Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"61 4","pages":"351-357"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.29399/npa.28712","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia.

Methods: A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed.

Results: A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone.

Conclusion: Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利培酮治疗首发精神分裂症疗效的meta分析。

导言首发精神分裂症是一种病因复杂的常见精神疾病。本荟萃分析评估了利培酮治疗首发精神分裂症患者的疗效：方法：我们进行了文献检索，以确定利培酮对首发精神分裂症疗效的研究。对文献进行了质量评估，然后进行了荟萃分析：结果：共收录了 15 篇文章（中文 6 篇，英文 9 篇）。荟萃分析显示，治愈率的差异具有统计学意义（相对风险 [RR]=0.51, 95% 置信区间 [CI]：0.46-0.57, p 结论：与对照组（包括安慰剂和其他抗精神病药物）相比，利培酮治疗首发精神分裂症患者的治愈率和有效率均有所提高。然而，它可能会增加锥体外系反应和体重增加的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Noropsikiyatri Arsivi-Archives of Neuropsychiatry CLINICAL NEUROLOGY-

CiteScore

1.70

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Archives of Neuropsychiatry (Arch Neuropsychiatry) is the official journal of the Turkish Neuropsychiatric Society. It is published quarterly, and four editions annually constitute a volume. Archives of Neuropsychiatry is a peer reviewed scientific journal that publishes articles on psychiatry, neurology, and behavioural sciences. Both clinical and basic science contributions are welcomed. Submissions that address topics in the interface of neurology and psychiatry are encouraged. The content covers original research articles, reviews, letters to the editor, and case reports.